Autopsy report · NCT05183139

A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma

“Business decision (no enrollment)”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 4

Sponsor

Takeda

Sponsor type

Industry

Conditions

Multiple Myeloma

Interventions

Ixazomib; Pomalidomide; Lenalidomide; Dexamethasone

Participants

0

Trials that died the same way

• A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria
  “Business decision due to enrollment challenges” (81% match in meaning)
• StrataPATH™ (Precision Indications for Approved Therapies)
  “Business decision and enrollment difficulties” (80% match in meaning)
• Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy
  “PI Decision based on no enrollment” (76% match in meaning)
• CorPath GRX STEMI Study
  “Low enrollment and sponsor business decision” (75% match in meaning)
• Safety and Feasibility Study of Cell Therapy in Treatment of Spinal Cord Injury
  “No enrollment.” (70% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.